Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

Blood (2021) 138 (25): 2655–2669.

https://doi.org/10.1182/blood.2020010477

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE ® Antibody Construct

Lea Pawlowsky, Bettina Brauchle, MSc, Maryam Kazerani Pasikhani, Ana Ogrinc Wagner, PhD, Veit Bücklein, MD, Felix S. Lichtenegger, MD, Roman Kischel, MD, Klaus H. Metzeler, MD, Karsten Spiekermann, MD, Michael Andreeff, MD PhD, Naval G. Daver, MD, Michael von Bergwelt, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 1265.

https://doi.org/10.1182/blood-2019-122415

Published: 2019

Journal Articles

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide

Blood (2019) 134 (Supplement_1): 4450.

https://doi.org/10.1182/blood-2019-130121

Published: 2019

Journal Articles

The Ratio of Costimulatory Vs Coinhibitory Molecules on AML Cells Determines the CD33-BiTE ® Mediated T-Cell Response

Anetta Marcinek, MSc, Bettina Brauchle, MSc, Dragica Udiljak, Roman Kischel, MD, Peter Kufer, MD, Karsten Spiekermann, MD, Michael von Bergwelt, MD, Felix S. Lichtenegger, MD, Marion Subklewe, MD

Blood (2018) 132 (Supplement 1): 1349.

https://doi.org/10.1182/blood-2018-99-116297

Published: 2018

Journal Articles

Midostaurin Reduces Bite® Mediated Cytotoxicity Against Acute Myeloid Leukemia

Bettina Lindl, Christina Krupka, PhD, Tara Chapman-Arvedson, Roman Kischel, MD, Peter Kufer, MD, Sascha Haubner, MD, Felix S. Lichtenegger, MD, Thomas Koehnke, MD, Klaus H. Metzeler, MD, Nikola Konstandin, PhD, Karsten Spiekermann, Wolfgang Hiddemann, MD PhD, Marion Subklewe, MD

Blood (2017) 130 (Supplement 1): 2656.

https://doi.org/10.1182/blood.V130.Suppl_1.2656.2656

Published: 2017

Journal Articles

Induction of Antigen-Specific T-Cell Responses through Dendritic Cell Vaccination in AML: Results of a Phase I/II Trial and Ex Vivo Enhancement By Checkpoint Blockade

Felix S. Lichtenegger, MD, Katrin Deiser, PhD, Maurine Rothe, Frauke M. Schnorfeil, PhD, Christina Krupka, PhD, Christian Augsberger, Thomas Köhnke, MD, Veit L. Bücklein, MD, Torben Altmann, MD, Andreas Moosmann, Monika Brüggemann, MD PhD, Mirjam H.M. Heemskerk, PhD, Georg Wittmann, MD, Beate Wagner, MD, Wolfgang Hiddemann, MD, Iris Bigalke, PhD, Gunnar Kvalheim, MD PhD, Marion Subklewe, MD

Blood (2016) 128 (22): 764.

https://doi.org/10.1182/blood.V128.22.764.764

Published: 2016

Journal Articles

Steroids Abrogate BiTE ® Antibody Construct-Mediated Cytotoxicity in Primary AML Cells

Christina Krupka, Bettina Lindl, Thomas Köhnke, MD, Julia Platzer, Lavinia Pachzelt, Felix S Lichtenegger, MD, Torben Altmann, Peter Kufer, MD, Roman Kischel, MD, Wolfgang Hiddemann, MD, PhD, Marion Subklewe, MD

Blood (2016) 128 (22): 3940.

https://doi.org/10.1182/blood.V128.22.3940.3940

Published: 2016

Journal Articles

Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE® Antibody Construct (AMG 330) Mediated Cytotoxicity

Christina Krupka, Thomas Köhnke, MD, Peter Kufer, Roman Kischel, Felix S. Lichtenegger, Franziska Brauneck, Stefan Rohling, Torben Altmann, Wolfgang Hiddemann, MD PhD, Marion S. Subklewe, MD

Blood (2015) 126 (23): 3677.

https://doi.org/10.1182/blood.V126.23.3677.3677

Published: 2015

Journal Articles

Next-Generation Dendritic Cell Vaccination in Postremission Therapy of AML: Results of a Clinical Phase I Trial

Katrin Deiser, Felix S. Lichtenegger, Frauke Schnorfeil, Thomas Koehnke, Torben Altmann, Veit Buecklein, Andreas Moosmann, Monika Brueggemann, Beate Wagner, Wolfgang Hiddemann, Iris Bigalke, Gunnar Kvalheim, Marion S. Subklewe, MD

Blood (2015) 126 (23): 3805.

https://doi.org/10.1182/blood.V126.23.3805.3805

Published: 2015

Journal Articles

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Christina Krupka, Franziska Brauneck, Felix S Lichtenegger, MD, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 986.

https://doi.org/10.1182/blood.V124.21.986.986

Published: 2014

Journal Articles

Targeting AML Using an Fc-Engineered BST1/CD157 Monoclonal Antibody

Christina Krupka, Anna Jansen, Irène Lassmann, Jon Terrett, PhD, Dee Aud, Rachel Dusek, PhD, Arnima Bisht, PhD, Esteban Pombo-Villar, PhD, Christian Rohlff, PhD, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Torben Altmann, MD, Klaus H Metzeler, MD, Michael Fiegl, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 987.

https://doi.org/10.1182/blood.V124.21.987.987

Published: 2014

Journal Articles

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Frauke M Schnorfeil, PhD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 3738.

https://doi.org/10.1182/blood.V124.21.3738.3738

Published: 2014

Journal Articles

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

Christina Krupka, Peter Kufer, Roman Kischel, Gerhard Zugmaier, Jan Bögeholz, Thomas Köhnke, Felix S. Lichtenegger, Stephanie Schneider, Klaus H. Metzeler, Michael Fiegl, Karsten Spiekermann, Patrick A. Baeuerle, Wolfgang Hiddemann, Gert Riethmüller, Marion Subklewe

Blood (2014) 123 (3): 356–365.

https://doi.org/10.1182/blood-2013-08-523548

Published: 2014

Includes: Supplemental data

Journal Articles

Improving Efficacy of Dendritic Cell Vaccination in AML: Optimization of the DC Generation Protocol and Maximization of T Cell Responses by Immune Checkpoint Blockade

Felix S Lichtenegger, MD, Barbara Beck, PhD, Christiane Geiger, PhD, Dieter Munker, Miriam Schlueter, Rika Draenert, MD, Frauke Schnorfeil, PhD, Gunnar Kvalheim, MD, PhD, Wolfgang Hiddemann, M.D., Dolores J Schendel, PhD, Marion Subklewe, MD

Blood (2013) 122 (21): 3492.

https://doi.org/10.1182/blood.V122.21.3492.3492

Published: 2013

Journal Articles

Pseudo-Exhaustion Of CD8 + T Cells in AML

Felix S. Lichtenegger, MD, Frauke M. Schnorfeil, PhD, Katharina Emmerig, Julia S. Neitz, Barbara Beck, PhD, Rika Draenert, MD, Wolfgang Hiddemann, M.D., Marion Subklewe, MD

Blood (2013) 122 (21): 2615.

https://doi.org/10.1182/blood.V122.21.2615.2615

Published: 2013

Journal Articles

Bifunctional Immunoactive siRNAs as an Approach to Personalized AML Therapy

Hanna Meinl, Marcus Zeitlhöfler, Samet Kocabey, Tim Liedl, PhD, Wolfgang Hiddemann, M.D., Marion Subklewe, MD, Stefan Endres, MD, Simon Rothenfußer, MD, Felix S Lichtenegger, MD

Blood (2013) 122 (21): 5036.

https://doi.org/10.1182/blood.V122.21.5036.5036

Published: 2013

Journal Articles

Coinhibitory Expression Profiling of AML Blasts Identifies HVEM as Prognostic Marker in AML

Felix S Lichtenegger, MD, Isabell Kondla, Michael Krempasky, Anna L Weber, Stephanie Schneider, PhD, Karsten Spiekermann, MD, Jan Braess, MD, Wolfgang Hiddemann, M.D., Marion Subklewe, MD

Blood (2013) 122 (21): 1359.

https://doi.org/10.1182/blood.V122.21.1359.1359

Published: 2013

Journal Articles

Evaluation Of CD33 Expression and Functional Analysis Of The CD33/CD3 Bispecific BiTE® Antibody AMG 330 In Primary AML Samples

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Jan Boegeholz, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Stephanie Schneider, PhD, Klaus H. Metzeler, MD, Michael Fiegl, MD, Karsten Spiekermann, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, Marion Subklewe, MD

Blood (2013) 122 (21): 239.

https://doi.org/10.1182/blood.V122.21.239.239

Published: 2013

Journal Articles

Costimulatory Expression Profiling of AML Blasts Identifies Surface Markers with High Correlation to Isolated NPM1 Mutation

Felix S Lichtenegger, MD, Michael Krempasky, Karsten Spiekermann, MD, Jan Braess, MD, Wolfgang Hiddemann, PhD, Marion Subklewe, MD

Blood (2011) 118 (21): 2511.

https://doi.org/10.1182/blood.V118.21.2511.2511

Published: 2011

Journal Articles

Composition of PBMC Population and Functionality of T- and NK-Cells in AML Patients Receiving Cytotoxic Maintenance Therapy,

Felix S Lichtenegger, MD, Robin Lorenz, Patrick Palluch, Ulrich Hoffmueller, MBA, PhD, Jan Braess, MD, Wolfgang Hiddemann, PhD, Barbara Beck, PhD, Marion Subklewe, MD

Blood (2011) 118 (21): 3601.

https://doi.org/10.1182/blood.V118.21.3601.3601

Published: 2011

NARROW

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE ® Antibody Construct

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide

The Ratio of Costimulatory Vs Coinhibitory Molecules on AML Cells Determines the CD33-BiTE ® Mediated T-Cell Response

Midostaurin Reduces Bite® Mediated Cytotoxicity Against Acute Myeloid Leukemia

Induction of Antigen-Specific T-Cell Responses through Dendritic Cell Vaccination in AML: Results of a Phase I/II Trial and Ex Vivo Enhancement By Checkpoint Blockade

Steroids Abrogate BiTE ® Antibody Construct-Mediated Cytotoxicity in Primary AML Cells

Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE® Antibody Construct (AMG 330) Mediated Cytotoxicity

Next-Generation Dendritic Cell Vaccination in Postremission Therapy of AML: Results of a Clinical Phase I Trial

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Targeting AML Using an Fc-Engineered BST1/CD157 Monoclonal Antibody

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

Improving Efficacy of Dendritic Cell Vaccination in AML: Optimization of the DC Generation Protocol and Maximization of T Cell Responses by Immune Checkpoint Blockade

Pseudo-Exhaustion Of CD8 + T Cells in AML

Bifunctional Immunoactive siRNAs as an Approach to Personalized AML Therapy

Coinhibitory Expression Profiling of AML Blasts Identifies HVEM as Prognostic Marker in AML

Evaluation Of CD33 Expression and Functional Analysis Of The CD33/CD3 Bispecific BiTE® Antibody AMG 330 In Primary AML Samples

Costimulatory Expression Profiling of AML Blasts Identifies Surface Markers with High Correlation to Isolated NPM1 Mutation

Composition of PBMC Population and Functionality of T- and NK-Cells in AML Patients Receiving Cytotoxic Maintenance Therapy,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only